The company
Nektar Therapeutics
NKTR · Nasdaq
NKTR stood above a rising 150-day average in 39 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 46.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 6
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $4.6M
- Officials’ trades on record
- 2
- Institutions holding
- 231 (+28)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 39 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
2 disclosed lines: House 2, Senate 0, executive 0; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Josh Gottheimer House: U.S. House ClerkNJ05 | sold | $1k–$15k | 21 Jun 2018filed 2 Oct 2018 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | bought | $1k–$15k | 6 Jun 2018filed 2 Oct 2018 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Howard W. RobinPresident & CEO | sold | 418at $71.98 | 18 Aug 2026filed 20 Aug 2026 |
| Jonathan ZalevskyChief R&D Officer | sold | 186at $71.98 | 18 Aug 2026filed 20 Aug 2026 |
| Jonathan ZalevskyChief R&D Officer | sold | 5,681at $70.00 | 30 Jun 2026filed 2 Jul 2026 |
| Howard W. RobinPresident & CEO | sold | 5,500at $60.81 | 17 Jun 2026filed 18 Jun 2026 |
| Howard W. RobinPresident & CEO | sold | 4,500at $61.65 | 17 Jun 2026filed 18 Jun 2026 |
| Howard W. RobinPresident & CEO | sold | 5,303at $59.97 | 16 Jun 2026filed 18 Jun 2026 |
| Howard W. RobinPresident & CEO | sold | 4,697at $60.71 | 16 Jun 2026filed 18 Jun 2026 |
| Jonathan ZalevskyChief R&D Officer | sold | 5,538at $60.71 | 15 Jun 2026filed 17 Jun 2026 |
| Howard W. RobinPresident & CEO | sold | 444at $65.51 | 19 May 2026filed 21 May 2026 |
| Jonathan ZalevskyChief R&D Officer | sold | 199at $65.51 | 19 May 2026filed 21 May 2026 |
| Howard W. RobinPresident & CEO | sold | 423at $73.00 | 18 Feb 2026filed 20 Feb 2026 |
| Jonathan ZalevskyChief R&D Officer | sold | 180at $73.00 | 18 Feb 2026filed 20 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 5,067,920$353.8M | +764,732+17.8% |
| Two Seas Capital LPadded · filed 12 Aug 2026 | 3,092,234$215.9M | +1,133,056+57.8% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 2,941,851$205.4M | +2,249,201+324.7% |
| BVF INCreduced · filed 14 Aug 2026 | 2,391,075$166.9M | -168,520−6.6% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,496,849$104.5M | +299,794+25.0% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 1,202,004$83.9M | +271,263+29.1% |
| Vestal Point Capital, LPadded · filed 14 Aug 2026 | 1,000,000$69.8M | +715,000+250.9% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 936,560$65.4M | +277,173+42.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 909,679$63.5M | +664,952+271.7% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 881,306$61.5M | +534,511+154.1% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.